EU projects

Pulsetto wins InoPažanga and secures EU funding

EU funding for clinical trials of the Pulsetto vagus nerve stimulator.

Project: validation of the safety and efficacy of the vagus nerve stimulator Pulsetto during clinical trials

UAB “Pulsetto” is proud to announce our victory in the prestigious InoPažanga competition, securing European Union funding for our groundbreaking project. This initiative aims to validate the safety and efficacy of our innovative vagus nerve stimulator, Pulsetto, through rigorous clinical trials. Recognising that clinical trials are crucial for health tech innovation, we are dedicated to ensuring that Pulsetto meets the highest standards, providing customers with reliable, evidence-based technology.

What the project will deliver

Upon the project’s completion, we will have developed an innovative, high-quality vagus nerve stimulator poised to compete successfully in the market. Our Pulsetto device will be accessible to the public and is expected to significantly enhance the quality of daily life by effectively combating stress. Beyond promoting relaxation, Pulsetto will help regulate food intake and feelings of satiety, improve sleep quality, and reduce fatigue. A key outcome of the project is to validate the safety, efficacy, and suitability of the Pulsetto vagus nerve stimulator.

With the support of the European Union, UAB “Pulsetto” is committed to advancing health technology and improving lives through our innovative solutions.

Project details

Project details
DetailInformation
FundingEuropean Regional Development Fund
Duration14 November 2023 – 9 October 2026
Project value1,307,288.47 EUR
EU funding618,022.69 EUR
Administrative institutionInnovation Agency
PartnerUAB Pikotera

More information: www.esinvesticijos.lt

Co-funded by the European Union

The project is financed by the European Regional Development Fund.